Biblio

Found 6 results

Filters: Keyword is Antineoplastic Combined Chemotherapy Protocols [Clear All Filters]

2022

Mukhtar R, W Symmans F, Esserman LJ. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply. JAMA Oncol. 2022 ;8(4):1.

Osdoit M, Yau C, W Symmans F, Boughey JC, Ewing CA, Balassanian R, Chen Y-Y, Krings G, Wallace AM, Zare S, et al. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 ;157(11):1034-1041.

A Chien J, Kyalwazi B, Esserman LJ. Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting. Cell Rep Med. 2022 ;3(6):100664.

Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRong Evely, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 ;40(6):609-623.e6.

Yau C, Osdoit M, Esserman LJ, W Symmans F. Survivorship after neoadjuvant chemotherapy - Authors' reply. Lancet Oncol. 2022 ;23(3):e96.

Marczyk M, Mrukwa A, Yau C, Wolf D, Chen Y-Y, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, et al. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 ;33(8):814-823.